Sign in Subscribe
Cancer

Cancer Research Reveals Link Between Side-Effect Bother and Treatment Discontinuation

Strategic Insights

— 1 min read

A study published in the Cancer journal has found that patients experiencing severe side-effect bother during cancer treatment are more likely to discontinue their therapy. The research, conducted by investigators at Northwestern University Feinberg School of Medicine, analyzed data from four clinical trials involving patients with breast cancer, melanoma, and chronic lymphocytic leukemia. The study's findings suggest that the Functional Assessment of Cancer Therapy (FACT) item GP5, which assesses side-effect bother, can be a valuable indicator of treatment tolerability and potential discontinuation.

Key Takeaways:

  • The study analyzed data from four clinical trials coordinated by the ECOG-ACRIN Cancer Research Group, covering breast cancer, melanoma, and chronic lymphocytic leukemia.
  • Patients reporting severe side-effect bother had approximately 2.8-6.8 times greater odds of early treatment discontinuation (ETD) due to adverse events (AEs).
  • The consistent association between GP5 responses and ETD suggests the GP5's ability to capture how well patients tolerate treatment, especially when side-effect bother is observed early in the course of treatment.
  • The study supports prior research demonstrating an association between severe side-effect bother and ETD among patients with newly diagnosed multiple myeloma.
  • The research concludes that the GP5's ability to capture side-effect bother can signal an opportunity to develop interventions to promote treatment adherence.
  • The study found significant associations between GP5 responses and ETD in each of the four trials, indicating a potential link between side-effect bother and treatment discontinuation.

Statistics:

  • Approximately 2.8-6.8 times greater odds of ETD among patients reporting severe side-effect bother (E1Z03: adjusted odds ratio [aOR], 2.82; 95% confidence interval [95% CI], 1.10-7.28; E1Z11: aOR, 4.10; 95% CI, 1.69-10.00; E1609: aOR, 6.77; 95% CI, 2.88-15.92; E1912: aOR, 4.15; 95% CI, 1.64-10.49).

Sources:

  • NewsRx. New Cancer Findings from Northwestern University Feinberg School of Medicine Outlined (Overall side-effect bother consistently associated with early treatment discontinuation due to adverse events in four clinical trials with various cancer ...). Cancer Weekly. November 4, 2025; p 1089.
  • Northwestern University Feinberg School of Medicine. "Overall side-effect bother consistently associated with early treatment discontinuation due to adverse events in four clinical trials with various cancer types and treatments." Cancer, 2025;131.
  • Wiley. "Cancer." onlinelibrary.wiley.com/journal/10.1002/(ISSN)1097-0142.

Read more